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The clinical effectiveness of sertraline in primary care and 
the role of depression severity and duration (PANDA): 
a pragmatic, double-blind, placebo-controlled randomised 
trial
Gemma Lewis, Larisa Duffy, Anthony Ades, Rebekah Amos, Ricardo Araya, Sally Brabyn, Katherine S Button, Rachel Churchill, Catherine Derrick, 
Christopher Dowrick, Simon Gilbody, Christopher Fawsitt, William Hollingworth, Vivien Jones, Tony Kendrick, David Kessler, Daphne Kounali, 
Naila Khan, Paul Lanham, Jodi Pervin, Tim J Peters, Derek Riozzie, George Salaminios, Laura Thomas, Nicky J Welton, Nicola Wiles, 
Rebecca Woodhouse, Glyn Lewis
Summary
Background Depression is usually managed in primary care, but most antidepressant trials are of patients from 
secondary care mental health services, with eligibility criteria based on diagnosis and severity of depressive symptoms. 
Antidepressants are now used in a much wider group of people than in previous regulatory trials. We investigated the 
clinical effectiveness of sertraline in patients in primary care with depressive symptoms ranging from mild to severe 
and tested the role of severity and duration in treatment response.
Methods The PANDA study was a pragmatic, multicentre, double-blind, placebo-controlled randomised trial of patients 
from 179 primary care surgeries in four UK cities (Bristol, Liverpool, London, and York). We included patients aged 
18 to 74 years who had depressive symptoms of any severity or duration in the past 2 years, where there was clinical 
uncertainty about the benefit of an antidepressant. This strategy was designed to improve the generalisability of our 
sample to current use of antidepressants within primary care. Patients were randomly assigned (1:1) with a remote 
computer-generated code to sertraline or placebo, and were stratified by severity, duration, and site with random block 
length. Patients received one capsule (sertraline 50 mg or placebo orally) daily for one week then two capsules daily for 
up to 11 weeks, consistent with evidence on optimal dosages for efficacy and acceptability. The primary outcome was 
depressive symptoms 6 weeks after randomisation, measured by Patient Health Questionnaire, 9-item version (PHQ-9) 
scores. Secondary outcomes at 2, 6 and 12 weeks were depressive symptoms and remission (PHQ-9 and Beck 
Depression Inventory-II), generalised anxiety symptoms (Generalised Anxiety Disorder Assessment 7-item version), 
mental and physical health-related quality of life (12-item Short-Form Health Survey), and self-reported improvement. 
All analyses compared groups as randomised (intention-to-treat). The study is registered with EudraCT, 2013-003440-22 
(protocol number 13/0413; version 6.1) and ISRCTN, ISRCTN84544741, and is closed to new participants.
Findings Between Jan 1, 2015, and Aug 31, 2017, we recruited and randomly assigned 655 patients—326 (50%) to 
sertraline and 329 (50%) to placebo. Two patients in the sertraline group did not complete a substantial proportion of 
the baseline assessment and were excluded, leaving 653 patients in total. Due to attrition, primary outcome analyses 
were of 550 patients (266 in the sertraline group and 284 in the placebo group; 85% follow-up that did not differ by 
treatment allocation). We found no evidence that sertraline led to a clinically meaningful reduction in depressive 
symptoms at 6 weeks. The mean 6-week PHQ-9 score was 7·98 (SD 5·63) in the sertraline group and 8·76 (5·86) in 
the placebo group (adjusted proportional difference 0·95, 95% CI 0·85–1·07; p=0·41). However, for secondary 
outcomes, we found evidence that sertraline led to reduced anxiety symptoms, better mental (but not physical) health-
related quality of life, and self-reported improvements in mental health. We observed weak evidence that depressive 
symptoms were reduced by sertraline at 12 weeks. We recorded seven adverse events—four for sertraline and three for 
placebo, and adverse events did not differ by treatment allocation. Three adverse events were classified as serious—
two in the sertraline group and one in the placebo group. One serious adverse event in the sertraline group was 
classified as possibly related to study medication.
Interpretation Sertraline is unlikely to reduce depressive symptoms within 6 weeks in primary care but we observed 
improvements in anxiety, quality of life, and self-rated mental health, which are likely to be clinically important. Our 
findings support the prescription of SSRI antidepressants in a wider group of participants than previously thought, 
including those with mild to moderate symptoms who do not meet diagnostic criteria for depression or generalised 
anxiety disorder.
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Introduction
Depression is a major contributor to the global burden 
of disease and by 2030 is predicted to be the leading 
cause of disability in high-income countries.1 People 
with depression are usually managed in primary care 
and SSRI antidepressants are often the first-line 
treatment.2,3 Prescriptions for antidepressants have 
risen dramatically in high-income countries over the 
past decade (70·9 million items were prescribed in 
England in 2018), leading to concerns that they are 
overprescribed.4
Existing evidence on the clinical effectiveness of anti-
depressants has been comprehensively summarised in a 
recent network meta-analysis, which reported small 
benefits of all antidepressants compared with placebo.5 
However, the constituent trials had many methodological 
limitations, were usually done decades ago for regulatory 
purposes, and generally were of poor quality, with 82% 
at moderate or high risk of bias.5 Larger, more recent 
placebo-controlled trials reported smaller antidepressant 
effect sizes, perhaps reflecting more rigorous methods.5
A more important criticism of the existing evidence 
is that most trials have used eligibility criteria based on 
diagnoses and severity. Primary care physicians see 
patients whose depressive symptoms range from mild to 
severe.2,6 Milder depressive symptoms can still cause 
distress and impairment,7 and it is common for primary 
care physicians to prescribe antidepressants when 
diagnostic criteria are not met.2,8 The use of anti-
depressants has increased and broadened since the 
original regulatory trials were done. Most antidepressants 
are now prescribed in primary care without any 
standardised assessment of depressive symptoms. It is 
difficult to generalise existing results to patients currently 
receiving treatment for depression.
Some studies have argued that antidepressants are 
more effective for patients with more severe symptoms9,10 
but most,11–14 although not all,15 meta-analyses of 
individual patient data do not support this. Systematic 
reviews on the effectiveness of antidepressants for 
patients with less severe depression have led to 
contradictory findings.16,17 The THREAD study was done 
in UK primary care and found small beneficial effects of 
SSRIs in patients with mild to moderate depressive 
symptoms, but comparison was with usual care rather 
than placebo.18
Research in context
Evidence before this study
Existing evidence on the effectiveness of antidepressants has 
been comprehensively summarised in a recent network 
meta-analysis by Cipriani and colleagues, which reported small 
benefits of all antidepressants compared with placebo. 
This meta-analysis included double-blind, randomised controlled 
trials published up to Jan 8, 2016, of adults meeting diagnostic 
criteria for depression. We updated this search for articles 
published up to Jan 31, 2019.  We also searched for trials 
including patients not meeting diagnostic criteria for depression. 
We searched PubMed and the Cochrane Central Register of 
Controlled Trials, for studies published in English, with the search 
terms “depress*” OR “dysthymi*” OR “adjustment disorder” 
OR “mood disorder” OR “affective disorder” OR “depress* 
symptoms” AND “antidepress*”. We did not find any individual 
trials of antidepressants compared with placebo in people with 
depression published since the review by Cipriani and colleagues. 
We found two systematic reviews of patients with subthreshold 
depressive symptoms. Most trials were done in secondary care, 
with patients who met diagnostic criteria and specified severity 
thresholds. These trials had many methodological limitations, 
were usually done several decades ago for regulatory purposes, 
and were generally of poor quality, with 82% rated by Cipriani 
and colleagues as having a moderate or high risk of bias. Some 
primary care trials have been done, but with similar limitations. 
Most studies of patients with subthreshold depression were low 
quality and reported inconsistent findings.
Added value of this study
To our knowledge, the PANDA trial is the largest 
placebo-controlled trial of an antidepressant not funded by 
the pharmaceutical industry. We did not restrict eligibility by 
specifying lower or higher thresholds of depression severity 
but relied instead upon clinical uncertainty. This improved 
generalisability to the relevant population in primary care. 
In our primary analyses, we did not find convincing evidence 
that sertraline led to clinically important reductions in 
depressive symptoms within six weeks, although there was 
weak evidence of a small benefit at 12 weeks. In secondary 
analyses, we found evidence that sertraline led to reduced 
anxiety symptoms, better mental health-related quality of life, 
and self-reported improvements in mental health.
Implications of all the available evidence
Sertraline leads to reduced anxiety symptoms and self-reported 
improvements in mental health within 6 weeks, but any effect 
on depressive symptoms takes longer to emerge and is more 
modest. Our findings support the prescription of SSRI 
antidepressants in a wider group of participants than previously 
thought, including those with mild to moderate symptoms 
who do not meet diagnostic criteria for depression or 
generalised anxiety disorder. Clinicians and patients should be 
aware of the symptoms that are likely to improve so that they 
can consider alternative management of depressive symptoms 
that might not respond.
Articles
www.thelancet.com/psychiatry   Vol 6   November 2019 905
Duration of depression, as well as severity, might help 
determine whether antidepressants could be beneficial.19 
Antidepressants can be effective for dysthymia—
depressive symptoms not meeting diagnostic criteria but 
present for 2 years or more.20 Dysthymia has been 
criticised for conflating severity and duration.19 To our 
knowledge, no previous trial has investigated the 
association between depression duration and anti-
depressant response.
In this study, we report on the clinical effectiveness of 
sertraline in a large sample of patients who presented to 
primary care with depressive symptoms. We also 
explored the influence of depression severity and 
duration. We did not restrict eligibility by specifying 
lower or higher thresholds of depression severity but 
relied instead upon clinical uncertainty,21,22 aiming to 
improve generalisability to the population receiving 
antidepressants in primary care.
Methods
Study design and participants
The PANDA study was a pragmatic, multicentre, double-
blind, placebo-controlled randomised trial of patients 
from 179 primary care surgeries in four UK cities (Bristol, 
Liverpool, London, and York).23 Patients were eligible for 
inclusion if they were aged 18 to 74 years and there was 
uncertainty (from general practitioner [GP] and patient) 
about the possible benefit of an antidepressant. Use of 
clinical uncertainty as an entry criterion avoids diagnostic 
or severity criteria and leads to a sample that is more 
generalisable to the population currently receiving 
antidepressant medication. Clinical uncertainty relies 
upon variation between doctors in how they make 
decisions and, with a sufficient number of doctors, this 
variation in practice leads to a wide and heterogeneous 
group of participants in the trial, reflecting clinical 
equipoise within the field.22 In our case, because primary 
care physicians do not use standardised assessments of 
depression, we expected trial participants to have a range 
of depressive symptom severity. Clinical uncertainty is 
also the ethical basis for randomised controlled trials.22,24,25 
Exclusion criteria were antidepressant treatment in past 
8 weeks; comorbid psychosis, schizophrenia, mania, 
hypomania, bipolar disorder, dementia, eating disorder, 
or major alcohol or substance abuse; and medical 
contraindications for sertraline.23
There were two methods of recruitment to the study. 
First, patients were referred during GP consultation. 
Second, GP practices searched computerised records for 
patients who presented with depression or depressive 
symptoms in the past two years. Patients were told that 
they had been referred to the study because their GP had 
identified them as having depression or low mood. 
A researcher then contacted patients by telephone to 
confirm eligibility. Since it was possible that some 
patients might not currently have depressive symptoms, 
researchers asked “firstly, I need to ask you do you want 
treatment for your depression at the moment?”. If the 
answer was no, the patient was excluded. Before 
randomisation, the patient’s GP was asked to approve 
inclusion in the trial and could exclude the patient if 
there was not clinical uncertainty.
All participants provided written informed consent. 
Ethics approval was from the National Research Ethics 
Service committee, East of England—Cambridge South 
(ref 13/EE/0418). The results presented here focus on the 
treatment effect of sertraline in primary care and are part 
of a larger research programme (NIHR RP-PG-0610-10048).
Randomisation and masking
Participants were randomly assigned (1:1) to sertraline or 
placebo by PRIMENT Clinical Trials Unit (CTU) with a 
remote computer-generated code, and were stratified by 
severity, duration, and site with random block length. 
Prespecified thresholds for stratification were total score 
(0–11, 12–19, and ≥20) and depression duration (<2 years 
or ≥2 years) at baseline on the Clinical Interview 
Schedule—Revised (CIS-R).26 Sertraline 50 mg tablets 
and placebo were encapsulated and were identical. 
Researchers and statisticians were masked to treatment 
allocation until completion of analyses. Primary care 
physicians were told the treatment allocation when 
participants finished their final assessment or withdrew 
from study medication, so they could discuss further 
treatment.
Procedures
Patients received one capsule (sertraline 50 mg or 
placebo orally) daily for one week then two capsules daily 
for up to 11 weeks, consistent with evidence on optimal 
dosages for efficacy and acceptability.27 After six weeks, 
medication could be increased to three capsules in 
consultation with the local principal investigator. Trial 
medication was sent by a trial pharmacy to the patient’s 
primary care physician (or home) after randomisation. 
Baseline assessments before randomisation and follow-
up assessments at 2 weeks, 6 weeks, and 12 weeks after 
randomisation took place in patients’ homes, primary 
care surgeries, or universities.23
We assessed patients’ depressive symptoms with 
the Patient Health Questionnaire, 9-item version 
(PHQ-9; available range 0–27, higher scores indicating 
more severe symptoms), a self-report measure of 
depressive symptoms in the past 2 weeks that is widely 
used in primary care.28 Self-report questionnaires avoid 
the possibility of observer bias associated with clinically 
rated outcomes29,30 and the PHQ-9 might be more 
responsive to change than other self-report measures.31,32 
We also assessed depressive symptoms with the Beck 
Depression Inventory (BDI-II). The BDI-II is a self report 
21-item scale that assesses the severity of depressive 
symptoms in the past 2 weeks. Scores range from 0–63, 
with higher scores indicating more severe symptoms. 
We assessed generalised anxiety symptoms with the 
For more on the software used 
for randomisation see 
https://sealedenvelope.com
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Generalised Anxiety Disorder Assessment 7-item version 
(GAD-7). The GAD-7 is a self-report measure of the 
severity of anxiety symptoms in the past 2 weeks, with 
possible scores ranging from 0–21 and higher scores 
indicating more severe symptoms. We derived separate 
physical and mental health-related quality of life scores 
with the 12-item Short-Form Health Survey (SF-12). 
Possible scores range from 0 to 100, with higher scores 
indicating better quality of life.
We used a five-item self-report adherence scale 
developed for the CoBalt study and a binary variable 
indicating at least 80% adherence.33 Patients were also 
asked about serious adverse events at each follow-up visit 
by use of open-ended questions. Physical symptoms that 
could be SSRI side-effects were recorded with a modified 
Toronto scale.34
The CIS-R is a computerised, self-administered, fully 
structured interview measuring 14 common mental 
disorder symptom groups.26 The CIS-R generates 
diagnoses meeting ICD-10 criteria for depressive or 
anxiety episodes, a total common mental disorders 
score, and a depression severity score (available range 
0–21) created by the sum of the following five symptoms: 
depression, depressive ideas, fatigue, concentration, 
and sleep problems. The total score in three categories 
was used for stratification. The severity score was used 
for the hypothesis that the treatment effect varied 
according to the severity of depressive symptoms at 
baseline. The CIS-R asks about duration of depressive 
symptoms with the following categories: less than 
2 weeks, between 2 weeks and 6 months, between 
6 months and 1 year, between 1 year and 2 years; 
between 2 years and 5 years; between 5 years and 
10 years, and more than 10 years. These categories were 
dichotomised into less than 2 years and 2 years or 
more.
Outcomes
The primary outcome was total score at 6 weeks on the 
PHQ-9.
Secondary outcomes were analysed as repeated 
measures across 2-week, 6-week, and 12-week follow-up 
assessments and included PHQ-9 and BDI-II total scores 
and remission (defined as a score of <10 on each 
measure), GAD-7 total scores, mental and physical 
health-related quality-of-life scores with the SF-12, and 
self-reported improvement in mental health. Self-
reported improvement was assessed by asking patients, 
“compared to when we last saw you, how have your 
moods and feelings changed?”. Responses were “I feel a 
lot better”, “I feel slightly better”, “I feel about the same”, 
“I feel slightly worse”, or “I feel a lot worse”.35,36 We 
created a binary variable of feeling the same or worse (0) 
and feeling better (1). Patients also completed the 
five-level EQ-5D instrument (for economic analyses) and 
emotional processing tasks, the results of which will be 
reported separately.
Statistical analyses
When originally devised, the primary aim of the PANDA 
trial was to investigate the severity and duration of 
depressive symptoms associated with a clinically 
important response to sertraline, as stated in the protocol 
paper23 and on ISCRTN. However, towards the later stages 
of designing the trial and when formulating the detailed 
analysis plan (uploaded before any analyses were done 
to UCL Discovery and approved by the trial steering 
committee), it became apparent that we would have 
insufficient statistical power to estimate plausible inter-
action effects that would allow us to investigate those 
aims. Therefore, our power calculation23 and primary 
analysis (as stated in the analysis plan) are based on a 
primary aim to examine the clinical effectiveness of 
sertraline versus placebo. Interactions between severity 
and duration at baseline and treatment allocation were 
planned as exploratory. Our protocol paper has described 
the power calculation in detail.23 Assuming a two-sided α 
of 5%, power of 90%, and 10% attrition, 547 participants 
were required to detect an 11% (relative) difference in 
scores between sertraline and placebo.
Analyses and reporting were in line with CONSORT 
guidelines. Primary and secondary outcomes were 
described in the approved protocol before the study 
started (appendix pp 59). The measure of self-reported 
improvement was added as a secondary outcome after 
the study started but before any analyses were done 
(appendix pp 25). When the study was registered on 
ISCRTN, the primary outcome was listed. Secondary 
outcomes were added later and were described and 
approved in the study protocol. All analyses compared 
groups as randomised (intention-to-treat). We compared 
the proportion of patients in each group who were 
categorised as adherent with Pearson’s χ² test. Physical 
symptoms that could be SSRI side-effects were compared 
by group with independent t-tests. Analyses of adherence 
and physical symptoms were done at each follow-up visit. 
We report serious adverse events during the trial 
according to treatment allocation.
The primary analysis was a linear regression of log-
transformed PHQ-9 scores at 6 weeks, adjusted for 
baseline PHQ-9 score and stratification variables (severity 
assessed by CIS-R in three categories, duration in 
two categories, and site). Regression coefficients from this 
model were the difference in geometric means of log-
transformed PHQ-9 scores between randomised groups. 
We exponentiated this regression coefficient to report the 
treatment effect as a ratio of the (geometric) mean PHQ-9 
score at 6 weeks in those allocated to sertraline to the 
(geometric) mean PHQ-9 score at 6 weeks in those 
allocated to placebo. The null value was 1 and proportions 
below 1 indicated fewer symptoms in the sertraline group. 
For example, a coefficient of 0·89 reflects PHQ-9 scores 
that were 11% lower in the sertraline than placebo group.
The proportional scale was chosen on the basis of 
model comparison between different scales. This choice 
See Online for appendix
For the ISCRTN listing see 
https://doi.org/10.1186/
ISRCTN84544741
For the uploaded analysis plan 
see http://discovery.ucl.ac.
uk/10041458/
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Figure: Trial profile
GP=general practitioner. 
PHQ-9=Patient Health 
Questionnaire, 9-item version.
35 719 patients identified as potentially eligible via record search 
 4074 removed from the initial list by GPs
31 645 sent an invitation letter
30 616 excluded
 3399 “no” replies
 27 217 no response
 1029 “yes” replies and checked for GP suitability
 136 excluded 
 110 not suitable
 20 GP suitability confirmations not received
 6 did not proceed to GP screen
 893 suitable 427 patients referred to study at consultation
1320 checked for eligibility
649 excluded
 113 not eligible
 376 declined to take part
 160 could not be reached for telephone screening
 671 eligible and proceeded to consenting and randomisation
 4 refused to consent
 667 consented and completed baseline assessment
 12 refused randomisation
 655 randomly assigned
329 assigned to placebo
 328 completed PHQ-9 at baseline
 1 did not complete PHQ-9 at baseline
29 withdrew
 22 not interested
 4 no time
 1 did not want to 
 take drug
 2 lost to follow-up
292 attended 2-week follow-up
 292 completed PHQ-9
 8 missed 2-week 
 follow-up
14 withdrew
 7 not interested
 3 no time
 3 did not want to 
 take drug
 1 lost to follow-up
 1 missed 6-week 
 follow-up
 3 missed 12-week 
 follow-up
285 attended 6-week follow-up and included
in primary analysis
 285 completed PHQ-9
18 withdrew
 15 not interested
 2 no time
 1 did not want to 
 take drug
265 attended 12-week follow-up
 263 completed PHQ-9
 2 did not complete PHQ-9
326 assigned to sertraline
 325 completed PHQ-9 at baseline
 1 did not complete PHQ-9 at baseline
33 withdrew
 22 not interested
 7 no time
 2 did not want to 
 take drug
 2 lost to follow-up
279 attended 2-week follow-up
 277 completed PHQ-9
 2 did not complete PHQ-9
12 missed 2-week 
 follow-up
18 withdrew
 11 not interested
 6 no time
 1 lost to follow-up
 6 missed 6-week 
  follow-up
267 attended 6-week follow-up and included
in primary analysis
 267 completed PHQ-9
 7 withdrew
 4 not interested
 3 no time
264 attended 12-week follow-up
 262 completed PHQ-9
 2 did not complete PHQ-9
2 did not complete a
 substantial proportion
 of the assessments
 2 missed 12-week 
 follow-up
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was supported by previous work showing benefits for 
choosing the scale. These benefits include variance 
stabilisation and overcoming the issue of baseline 
dependence.35,37 A proportional model is also plausible, as 
it seems unlikely that a treatment would lead to the same 
difference in means in those starting at a high score 
compared with those with a low score.
Given our interest in the relationship between severity 
and treatment effect, we included baseline depression 
CIS-R scores in the primary analysis. The primary 
analysis was also done without the CIS-R depression 
score, to examine the possible influence of collinearity. 
We investigated how robust findings were to the model 
specification by comparison with a Poisson model.
We calculated linear multilevel models for continuous 
secondary outcomes (PHQ-9, BDI-II, GAD-7, and 
SF-12 physical and mental health quality of life) with log-
transformed PHQ-9, BDI-II, and GAD-7 scores and raw 
SF-12 scores, as stated in the analysis plan. Logistic 
multilevel models were calculated for binary secondary 
outcomes (remission on PHQ-9 and BDI-II, and self-
reported improvement). Models included continuous 
baseline measurement of the outcome, CIS-R depression 
severity score, and stratification variables. For primary 
and secondary outcomes, we report interactions between 
treatment allocation and baseline CIS-R depression 
severity score and duration.
For sensitivity analyses, we reported primary and 
secondary outcomes after adjustment for variables that 
were possibly imbalanced at baseline, which were 
identified using descriptive statistics. We investigated 
possible clustering within surgeries by calculating the 
intraclass correlation coefficient using multilevel models, 
with a random intercept for surgeries. We reported the 
treatment effect from this multilevel model to assess 
whether clustering had an influence.
We did two sensitivity analyses to investigate the 
possible effect of missing data. First, we adjusted for 
baseline variables associated with missing outcome 
data. Second, we used multiple imputation by chained 
equations to replace missing data. We assumed 
missing ness was dependent on observed data and 
imputed 50 datasets. Imputation models included 
variables from our models and variables associated 
with missing data, with pooled results obtained using 
Rubin’s rules.38 Our post-hoc analyses are detailed in 
the appendix (p 4).
The study was overseen by a data monitoring 
committee. All analyses were done in STATA version 15. 
The study is registered with EudraCT, 2013-003440-22 
(protocol number 13/0413; version 6.1), and ISRCTN, 
ISRCTN84544741.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
Sertraline (n=324) Placebo (n=329) Overall (n=653)
Site*
Bristol 131 (40%) 134 (41%) 265 (41%)
Liverpool 58 (18%) 58 (18%) 116 (18%)
London 69 (21%) 73 (22%) 142 (22%)
York 66 (20%) 64 (19%) 130 (20%)
CIS-R total score*
0–11 67 (21%) 62 (19%) 129 (20%)
12–19 84 (26%) 89 (27%) 173 (26%)
≥20–49 173 (53%) 178 (54%) 351 (54%)
CIS-R depression duration (years)*
<2 218 (67%) 221 (67%) 439 (67%)
≥2 106 (33%) 108 (33%) 214 (33%)
Age (years)
18–34 132 (41%) 134 (41%) 266 (41%)
35–54 125 (39%) 134 (41%) 259 (40%)
55–74 67 (21%) 61 (19%) 128 (20%)
Sex
Female 203 (63%) 181 (55%) 384 (59%)
Male 121 (37%) 148 (45%) 269 (41%)
ICD-10 CIS-R depression diagnosis†
Yes 167 (52%) 188 (57%) 355 (54%)
No 156 (48%) 141 (43%) 297 (46%)
ICD-10 CIS-R anxiety diagnosis†
Yes 144 (45%) 155 (47%) 299 (46%)
No 179 (55%) 174 (53%) 353 (54%)
Ethnicity†
White 294 (91%) 285 (87%) 579 (89%)
Ethnic minority 29 (9%) 44 (13%) 73 (11%)
Marital status†
Married or living as married 116 (36%) 139 (42%) 255 (39%)
Single 152 (47%) 144 (44%) 296 (45%)
Separated, divorced, or widowed 55 (17%) 46 (14%) 101 (15%)
Employment status†
In paid employment 209 (65%) 224 (68%) 433 (66%)
Not employed 114 (35%) 105 (32%) 219 (34%)
Financial difficulty†
Living comfortably or doing alright 180 (56%) 184 (56%) 364 (56%)
Just about getting by 101 (31%) 103 (31%) 204 (31%)
Finding it difficult or very difficult 42 (13%) 42 (13%) 84 (13%)
Highest educational qualification†
A Level or higher 216 (67%) 234 (71%) 450 (69%)
GCSE, standard grade, or other 92 (28%) 77 (23%) 169 (26%)
No formal qualification 15 (5%) 18 (5%) 33 (5%)
Depression in the past†
Yes 259 (80%) 263 (80%) 522 (80%)
No 64 (20%) 66 (20%) 130 (20%)
Antidepressant in the past†
Yes 191 (59%) 200 (61%) 391 (60%)
No 132 (41%) 129 (39%) 261 (40%)
Patient Health Questionnaire, 9-item 
version total score (possible range 0–27)
11·79 (5·90) 12·20 (5·71) 12·00 (5·80)
CIS-R total score (possible range 0–64) 20·89 (10·09) 21·60 (10·19) 21·25 (10·14)
(Table 1 continues on next page)
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all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Jan 1, 2015, and Aug 31, 2017, we recruited and 
randomly assigned 655 patients—326 (50%) to sertraline 
and 329 (50%) to placebo (figure). Two patients in 
the sertraline group did not complete a substantial 
proportion of the baseline assessment and were excluded, 
leaving 653 patients in total included in analyses. Patients 
were recruited from 179 GP surgeries (appendix p 7). 
Patients who were invited to participate and those who 
participated were similar in age and sex (appendix p 8).
The proportions of patients attending each follow-up 
visit were similar in both trial groups and we found no 
statistical evidence for a difference in attrition by group 
(figure). Missing follow-up data were more likely in 
patients who were recruited in London, younger, ethnic 
minority, single, having financial difficulties, and those 
with no formal qualifications, and higher baseline 
PHQ-9, BDI-II, GAD-7, and life-event scores (appendix 
pp 9–10).
Baseline characteristics of the sample were similar 
between treatment groups (table 1). Overall, the mean 
patient age was 39·7 years (SD 14·96), 384 (59%) 
participants were female, and 433 (66%) were employed. 
On the CIS-R, 355 (54%) patients met ICD-10 criteria for 
depression, 299 (46%) patients met generalised anxiety 
criteria, 197 (30%) met both depression and generalised 
anxiety disorder criteria, and 96 (15%) met criteria for 
mixed anxiety and depressive disorder (scoring 12 or 
more but not meeting diagnostic criteria for depression 
or anxiety).39 99 (15%) patients did not meet any 
diagnostic criteria for depression or anxiety. The mean 
PHQ-9 score was 12·0 (SD 5·8) and 405 (62%) patients 
exceeded a score of 10 (the recommended threshold for 
clinical use). 391 (60%) patients had received anti-
depressants previously and 522 (80%) patients reported 
previous depression. In the sertraline group, there was a 
higher proportion of women, and lower proportions of 
those who were married or living as married and meeting 
ICD-10 depression criteria.
563 (86%) of 653 randomised patients provided the 
date they started medication (median 8 days after 
randomisation, IQR 6–11, range 1–70). There were delays 
with follow-up assessments so that these were carried 
out a median of 1 week, 5 weeks, and 11 weeks after 
patients started medication.
Adherence was greater than 80% at all timepoints and 
we observed no evidence of a difference in adherence 
between treatment groups (appendix p 11). More patients 
in the sertraline group than the placebo group thought 
they were taking sertraline at 2 weeks, 6 weeks, and 
12 weeks (appendix p 11).
Due to attrition and missing data, 550 patients were 
included in the analysis of the primary outcome. Mean 
PHQ-9 scores at 6 weeks were 7·98 (SD 5·63) in patients 
allocated to sertraline and 8·76 (5·86) in patients 
allocated to placebo (table 2). After adjustment for 
baseline scores and stratification variables, the adjusted 
proportional difference between sertraline and placebo 
Sertraline (n=324) Placebo (n=329) Overall (n=653)
(Continued from previous page)
CIS-R depression severity score 
(possible range 0–21)‡
10·40 (4·95) 10·76 (4·84) 10·58 (4·90)
Beck Depression Inventory, second 
edition total score (possible range 0–63)
24·01 (10·54) 23·87 (10·07) 23·94 (10·30)
Generalised Anxiety Disorder 
Assessment, 7-item version score 
(possible range 0–21)
9·44 (5·39) 9·42 (5·17) 9·43 (5·28)
Social support score 
(possible range 1–24)
12·46 (4·01) 12·83 (3·63) 12·64 (3·82)
SF-12 mental health subscale 
(possible range 0–100)
32·96 (10·99) 31·98 (11·08) 32·47 (11·04)
SF-12 physical health subscale 
(possible range 0–100)
52·19 (9·36) 51·95 (10·04) 52·07 (9·70)
Number of life events in past 6 months 1·20 (1·20) 1·24 (1·19) 1·22 (1·19)
Number of physical symptoms in past 
2 weeks
10·01 (4·44) 10·12 (5·42) 10·07 (5·42)
Frequency of physical symptoms 
(possible range 55–112)§
43·86 (11·13) 43·95 (10·80) 43·91 (10·96)
Data are n (%) or mean (SD). One person in the placebo group was missing the PHQ-9 score at baseline and one person in 
the sertraline group was missing the CIS-R depression score at baseline. CIS-R=Clinical Interview Schedule—Revised. 
SF-12= Short-Form Health Survey. *The total CIS-R score assesses the severity of symptoms of common mental disorders. 
The total CIS-R score in three categories was a stratification variable at randomisation: 0–11 (minimal symptoms), 
12–19 (moderate to severe symptoms), and ≥20 (severe symptoms). †A CIS-R diagnosis used the criteria and threshold 
required to meet an ICD-10 clinical diagnosis of depression or anxiety. CIS-R data were missing for one person. ‡The CIS-R 
depression severity score (possible range 0–21) assesses the severity of depressive symptoms. §How often during the past 
2 weeks the patient had each symptom: 1 (not at all), 2 (several days), 3 (more than half the days), and 4 (nearly every day).
Table 1: Baseline characteristics
Sertraline Placebo Adjusted proportional 
difference* (95% CI)
p value
n Mean (SD) n Mean (SD)
Model 1† 266 7·98 (5·63) 284 8·76 (5·86) 0·95 (0·85–1·07) 0·41
Model 2‡ 266 7·98 (5·63) 284 8·76 (5·86) 0·94 (0·84–1·05) 0·30
Model 3§ 266 7·98 (5·63) 284 8·76 (5·86) 0·95 (0·85–1·05) 0·31
Model 4¶ 266 7·98 (5·63) 282 8·81 (5·85) 0·94 (0·85–1·05) 0·28
Model 5|| 324 8·25 (5·81) 329 8·88 (5·87) 0·96 (0·86–1·08) 0·50
Model 6** 324 8·25 (5·81) 329 8·88 (5·87) 0·95 (0·85–1·07) 0·39
Means (SDs) are for non-log-transformed PHQ-9 scores at 6 weeks. One person in the placebo group was missing the 
PHQ-9 score at baseline and one person in the sertraline group was missing the CIS-R depression score at baseline. 
These individuals were excluded from the regression model of the primary outcome at 6 weeks. PHQ-9=Patient Health 
Questionnaire, 9-item version. CIS-R=Clinical Interview Schedule—Revised. *All models use a log-transformed 
PHQ-9 score as the outcome. Adjusted proportional difference can be interpreted as the difference in scores between 
randomised groups expressed as a proportion (or percentage). †Primary analysis model: intention-to-treat analysis 
adjusted for baseline PHQ-9 and CIS-R depression scores and stratification variables (total CIS-R score in three categories, 
duration of depressive episode in two categories, and site; n=550). ‡Model 1 adjusted for variables showing imbalance at 
baseline (sex, ICD-10 depression diagnosis, marital status; n=550). §Model 1 adjusted for possible clustering effects using 
a random effect for general practices (n=550). ¶Model 1 adjusted for baseline variables associated with missing outcome 
data (age, ethnicity, marital status, financial difficulty, ICD-10 anxiety diagnosis, used antidepressants in the past, Beck 
Depression Inventory, second edition score, number of life events, Generalised Anxiety Disorder Assessment, 7-item 
version score; n=550). ||Model 1 with missing data replaced by multiple imputation (n=653). **The imputed model 
(model 5) adjusted for variables showing imbalance at baseline (sex, ICD-10 depression diagnosis, marital status; n=653).
Table 2: Analyses of primary outcome (log-transformed PHQ-9 scores at 6 weeks)
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was 0·95 (95% CI 0·85–1·07; p=0·41; model 1; table 2). 
This result changed very little after adjustment for 
variables showing imbalance (model 2; table 2). We 
found little evidence of clustering by surgery (intracluster 
correlation coefficient 0·04, 95% CI 0·00–0·01) and no 
evidence that clustering altered the treatment effect 
(model 3; table 2). The treatment effect was similar after 
considering missing data (models 4, 5, 6; table 2).
We observed an association between baseline CIS-R 
depression severity and PHQ-9 scores at 6 weeks, with a 
3% increase in PHQ-9 scores for each unit increase in 
CIS-R depression score (adjusted proportional difference 
1·03, 95% CI 1·01–1·05; p=0·0046). We found no 
evidence of an association between baseline depression 
duration and PHQ-9 score at 6 weeks (1·08, 95% CI 
0·96–1·22; p=0·19). We observed no evidence that 
treatment response varied with depression severity 
(p=0·9907) or duration (p=0·8203).
The result of the primary analysis did not change after 
we excluded baseline CIS-R depression scores to explore 
possible multicollinearity (adjusted proportional dif-
ference 0·96, 95% CI 0·85–1·07; p=0·41). The result of 
the primary analysis was consistent with a negative 
binomial model (chosen as an extension of the Poisson 
model because PHQ-9 variance at 6 weeks was larger 
than the mean).
The adjusted proportional difference in PHQ-9 scores 
across all timepoints was 0·93 (95% CI 0·86–1·01, 
p=0·11; table 3). At 12 weeks, PHQ-9 scores were 13% 
lower (0·87, 95% CI 0·79–0·97) in the sertraline group. 
We observed similar results for the BDI-II (table 3). We 
observed evidence that differences in GAD-7 scores 
became larger over time (p=0·0075). At 6 weeks, 
GAD-7 scores were 21% lower (adjusted proportional 
difference 0·79, 95% CI 0·70–0·89) in those allocated to 
sertraline than in those allocated to placebo. Mental 
health-related quality of life scores were higher 
(2·41, 95% CI 1·14–3·96, p=0·00021) in the sertraline 
group than in the placebo group, with no evidence that 
differences varied over time (p=0·22). We observed no 
evidence of a difference in physical health-related quality 
of life (table 3).
We found evidence that sertraline led to increased odds 
of remission at 12 weeks (but not 6 weeks) and this 
evidence was stronger for BDI-II than PHQ-9 (table 4; 
appendix p 24). Patients in the sertraline group had 
increased odds of reporting feeling better than the same 
or worse (adjusted OR 1·96, 95% CI 1·45–2·63; 
p<0·0001), with no evidence that this difference varied 
over time (p=0·16).
Analysis of secondary outcomes was unaffected by 
adjustment for variables that were imbalanced at baseline 
(appendix pp 13–14). We observed no evidence that treat-
ment response for secondary outcomes varied according 
to severity or duration of symptoms. Results of our post-hoc 
analyses are presented in the appendix (pp 15–24).
We recorded seven adverse events—four in the sertraline 
group and three in the placebo group (appendix p 12). 
Three adverse events were classified as serious—two in 
the sertraline group and one in the placebo group. 
One serious adverse event in the sertraline group was 
classified as possibly related to study medication and two 
Sertraline Placebo Adjusted proportional 
difference* (95% CI)
p value
n Mean (SD) n Mean (SD)
PHQ-9
Follow-up assessment (weeks)
2 277 9·94 (5·83) 292 10·32 (5·55) 0·96 (0·87 to 1·07) ··
6 266 7·98 (5·63) 284 8·76 (5·86) 0·96 (0·86 to 1·07) ··
12 262 6·90 (5·83) 263 8·02 (6·12) 0·87 (0·79 to 0·97) ··
Over time† ·· ·· ·· ·· 0·93 (0·86 to 1·01) 0·11
Group by time 
interaction
·· ·· ·· ·· ·· 0·0905
Beck Depression Inventory, second edition
Follow-up assessment (weeks)
2 273 18·77 (11·08) 286 19·10 (11·17) 0·99 (0·97 to 1·10) ··
6 266 14·82 (10·44) 285 15·91 (10·74) 0·95 (0·85 to 1·07) ··
12 256 12·44 (10·96) 259 14·78 (11·70) 0·84 (0·74 to 0·95) ··
Over time† ·· ·· ·· ·· 0·93 (0·84 to 1·21) 0·012
Group by time 
interaction
·· ·· ·· ·· ·· 0·015
GAD-7
Follow-up assessment (weeks)
2 277 7·55 (5·49) 291 8·16 (5·26) 0·91 (0·82 to 1·03) ··
6 264 5·55 (5·19) 284 6·96 (5·24) 0·79 (0·70 to 0·89) ··
12 263 4·95 (5·30) 263 6·27 (5·28) 0·77 (0·68 to 0·87) ··
Over time† ·· ·· ·· ·· 0·83 (0·75 to 0·91) <0·0001
Group by time 
interaction
·· ·· ·· ·· ·· 0·0075
SF-12 mental health
Follow-up assessment (weeks)
2 275 37·32 (11·47) 291 35·37 (11·36) 1·58 (–0·10 to 3·26) ··
6 254 41·95 (12·35) 277 38·67 (11·91) 2·90 (1·17 to 4·63) ··
12 263 42·70 (12·91) 264 39·71 (11·87) 2·85 (1·12 to 5·47) ··
Over time† ·· ·· ·· ·· 2·41 (1·14 to 3·69) 0·0002
Group by time 
interaction
·· ·· ·· ·· ·· 0·22
SF-12 physical health
Follow-up assessment (weeks)
2 275 51·92 (9·18) 291 52·40 (6·64) –0·71 (–1·75 to 0·34) ··
6 245 51·98 (8·39) 277 51·76 (9·90) –0·36 (–1·44 to 0·71) ··
12 263 51·92 (8·53) 264 52·50 (9·99) –0·89 (–1·96 to 0·19) ··
Over time† ·· ·· ·· ·· –0·66 (–1·48 to 0·17) 0·12
Group by time 
interaction
·· ·· ·· ·· ·· 0·79
PHQ-9=Patient Health Questionnaire, 9-item version. SF-12= Short-Form Health Survey. CIS-R=Clinical Interview 
Schedule—Revised. *These models used a log-transformed PHQ-9 score as the outcome. Adjusted proportional 
differences can be interpreted as the difference in scores between randomised groups expressed as a proportion 
(or percentage). All multilevel models were adjusted for baseline measure of each outcome (continuous), baseline 
CIS-R depression severity score, and stratification variables (baseline total CIS-R score in three categories, duration of 
depressive episode in two categories, and site). †Calculated using data from all three follow-ups combined.
Table 3: Repeated measures analyses of continuous secondary outcomes at 2 weeks, 6 weeks, and 12 weeks
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in the placebo group were classified as not related or 
unlikely to be related (appendix p 12). We found no 
evidence of a difference in the number of physical 
symptoms between groups (appendix p 12). 59 patients 
chose to increase their dose to 150 mg—37 (11%) in the 
placebo group and 22 (7%) in the sertraline group 
(p=0·047). We are aware of three incidents in which the 
capsule was broken. One of these incidents was intentional, 
although the participant drew the wrong conclusion about 
allocation. The other two incidents were inadvertent. The 
three affected participants were withdrawn from study 
medication once we were aware of these incidents.
Discussion
In our primary analysis, we did not find convincing 
evidence that sertraline led to a greater reduction in 
depressive symptoms compared with placebo within 
6 weeks. However, in our secondary analyses we found 
weak evidence that sertraline reduced depressive 
symptoms at 12 weeks compared with placebo. This effect 
was small, but does not exclude the possibility of a clinically 
important effect on depressive symptoms by 12 weeks.
In our secondary analyses, we found evidence that 
sertraline reduced generalised anxiety symptoms at 
6 weeks and 12 weeks compared with placebo. We also 
found evidence that sertraline led to better mental (but 
not physical) health-related quality of life and self-rated 
improvement in mental health.
Although results from secondary analyses should be 
interpreted with caution, statistical evidence for all our 
secondary outcomes (except depression) was strong. In 
particular, self-reported improvements in mental health 
can be used to calculate minimal clinically important 
differences and can be regarded as patient-centred 
indicators of clinically meaningful change.40 Depressive 
and anxiety symptoms often occur together and comorbid 
anxiety symptoms have been associated with poorer quality 
of life in people with depressive symptoms.41,42 We have 
found important evidence that sertraline can lead to clinical 
benefits for patients in primary care with depressive 
symptoms. However, these benefits occur mainly through 
improvements in anxiety symptoms and quality of life 
rather than reductions in depressive symptoms.
We found no evidence that severity or duration of 
depressive (or anxiety) symptoms affected treatment 
response, although analyses using interaction terms 
lacked statistical power. We found that duration of 
symptoms was not associated with outcome once severity 
of symptoms had been accounted for, suggesting that an 
interaction with treatment response is unlikely.
Sertraline has a similar pharmacological profile to 
other SSRIs and acts via a similar mechanism.5 
Therefore, we would expect our results to apply to other 
SSRIs when used in this population. Generalising our 
findings to antidepressants of other classes is more 
difficult, although there are similarities in the mechanism 
of action of all commonly used antidepressants.43
To our knowledge, the PANDA trial is the largest 
individual placebo-controlled trial of an antidepressant 
not funded by the pharmaceutical industry. Our trial had 
more attrition than predicted but recruited more 
participants than our target and had power to detect an 
11% reduction in symptoms—enough to detect a 
clinically important difference. Clinical trials are often 
criticised for using narrow inclusion criteria, which can 
reduce external validity.25 We used clinical uncertainty as 
an entry criterion, which avoids reliance upon diagnostic 
or severity criteria that have never been validated as an 
indication for antidepressants. Participants in our study 
ranged from those with very few depressive symptoms to 
those with severe depressive symptoms, therefore our 
results are more readily generalisable to the population 
currently receiving antidepressants in primary care than 
are the results of previous trials. Many people in our 
sample had very severe depression, suggesting that there 
is uncertainty about prescription of antidepressants in 
primary care at all levels of severity.
Use of clinical uncertainty as an entry criterion could 
have potential disadvantages. If patients with few 
depressive symptoms were less likely to respond to 
Sertraline Placebo Adjusted* OR 
(95% CI)
p value
n n (%) n n (%)
Patient Health Questionnaire, 9-item version remission
Follow-up assessment (weeks)
2 277 145 (52%) 292 136 (47%) 1·36 (0·76–2·41) ··
6 266 169 (63%) 284 164 (58%) 1·30 (0·72–2·34) ··
12 262 190 (73%) 263 170 (65%) 1·75 (0·94–3·27) ··
Over time† ·· ·· ·· ·· 1·44 (0·93–2·22) 0·10
Group by time 
interaction
·· ·· ·· ·· ·· 0·49
Beck Depression Inventory, second edition remission
Follow-up assessment (weeks)
2 273 58 (21%) 286 58 (20%) 1·01 (0·52–1·98) ··
6 266 94 (35%) 285 91 (32%) 1·28 (0·70–2·35) ··
12 256 131 (51%) 259 102 (39%) 2·69 (1·46–4·97) ··
Over time† ·· ·· ·· ·· 1·58 (1·00–2·47) 0·049
Group by time 
interaction
·· ·· ·· ·· ·· 0·012
Feeling better (self-rated improvement)
Follow-up assessment (weeks)
2 279 110 (39%) 292 89 (30%) 1·64 (1·06–2·53) ··
6 267 157 (59%) 285 132 (46%) 1·90 (1·24–2·91) ··
12 264 156 (59%) 265 112 (42%) 2·42 (1·56–3·75) ··
Over time† ·· ·· ·· ·· 1·96 (1·45–2·63) <0·0001
Group by time 
interaction
·· ·· ·· ·· ·· 0·16
CIS-R=Clinical Interview Schedule—Revised. *All multilevel models were adjusted for baseline measure of each 
outcome (continuous), baseline CIS-R depression severity score, and stratification variables (baseline total CIS-R score 
in three categories, duration of depressive episode in two categories, and site). †Calculated using data from all three 
follow-ups combined.
Table 4: Repeated measures analyses of binary secondary outcomes at 2 weeks, 6 weeks, and 12 weeks
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antidepressants, this might have reduced the treatment 
effect, but we did not find any suggestion of this. We also 
observed strong evidence of a treatment effect for anxiety 
symptoms despite our broad inclusion criteria.
Reliance upon clinical uncertainty will exclude those 
for whom a clinician is certain that antidepressants are 
indicated. We would expect people with the most severe 
depression to be somewhat underrepresented in the trial. 
However, this effect should be modest given the very 
wide range of depression severity in our sample. Use of 
clinical uncertainty as an entry criterion requires many 
clinicians to participate in a study to encompass the 
whole range of clinical practice. We included 179 practices 
from four UK cities, therefore it is unlikely that we are 
reflecting idiosyncratic practice. Instead, our sample 
most likely reflects the diverse decisions made by many 
doctors over a broad range of uncertainty.
There are marked similarities between the behaviour 
of doctors and patients in primary care within high-
income countries, despite divergent health systems. 
Antidepressant prescribing has increased in all high-
income countries over the past two decades.44 A similar 
trial in other high-income countries would probably 
identify participants over a wide range of depression 
severities and include many people with anxiety 
symptoms. Our main conclusions about the benefits of 
sertraline on anxiety rather than depressive symptoms 
should be generalisable to other high-income countries.
In the PANDA trial, 115 (46%) participants on 
sertraline thought they were taking the active drug at 
6 weeks compared with 52 (19%) participants on 
placebo. In other SSRI trials that have assessed patient 
beliefs about the medication that they are taking,45–48 
only one study45 found evidence that patients can 
distinguish active treatment from placebo. We consid-
ered two possible explanations for this finding in 
our trial. First, patients detected an improvement in 
their symptoms, therefore thought they were taking 
sertraline. Second, patients could detect being on 
sertraline because of physical or psychological effects 
that we did not measure. We found no evidence that 
side-effects differed by study group, therefore it is 
unlikely that reported adverse effects systematically led 
to a difference in patients guessing whether they were 
on sertraline or placebo.
The possibility that adverse effects of antidepressants 
could lead to unblinding and an inadvertent placebo effect 
has been raised previously.49 Such a placebo effect should 
lead to a difference in all outcomes. In our trial, anxiety, 
quality of life, and self-reported improvement measures 
showed greater changes than depressive symptom 
measures. This observation reduces the likelihood that 
differences between sertraline and placebo were explained 
purely by the possibility of unblinding.
Medication was encapsulated so participants could, in 
principle, break open the capsule and discover if there was 
a tablet included. We are aware of three incidents when 
this occurred. All three participants stopped the study 
medication once this had occurred and we do not think 
the encapsulation of the medication had an overall effect 
on the blinding of assessments in the trial.
Patients from record searches had less severe depressive 
and anxiety symptoms but were more likely to have taken 
antidepressants previously. These differences had no 
influence on treatment effects (appendix pp 19–21). 
Current practice in UK primary care is to engage with 
patients’ views and to share decision making.50 Therefore, 
patients who present to clinicians with mental health 
problems and ask for antidepressants will usually be 
prescribed these. Patients we identified through record 
searches who wanted treatment for their depressive 
symptoms are also those for whom there might be clinical 
uncertainty. GPs could exclude anyone who was recruited 
through record searches.
Our finding that sertraline was not effective for 
depressive symptoms at 6 weeks is inconsistent with 
previous studies.5 Antidepressants could have an effect 
on depressive symptoms that is not large enough to be 
detected in a trial of this size. A meta-analysis by Cipriani 
and colleagues5 reported a standardised difference in 
means of –0·27 (95% CI –0·34 to –0·21) for sertraline 
versus placebo at a median follow-up of 8 weeks. This effect 
size is considerably larger than the –0·09 (–0·23 to 0·05) 
standardised difference in means from our trial at 6 weeks 
so the explanation of our trial being too small to detect the 
effect reported by Cipriani and colleagues5 seems unlikely. 
Our findings at 12 weeks of a –0·18 standardised mean 
difference (95% CI –0·33 to –0·03) are closer to the result 
reported by Cipriani and colleagues.5
Previous studies have used observer-rated scales to 
assess depression, such as the Hamilton Depression 
Scale.30 Unlike our self-reported scales, these measures 
allow interviewer discretion and increase the possibility 
of observer bias. Beneficial effects of sertraline on anxiety 
and self-reported improvement might therefore lead to a 
so-called halo effect, such that observers rate depressive 
symptoms as improved. There is evidence that observer 
rating can bias results of depression and anxiety 
assessments.30 The Hamilton Depression Scale also 
contains questions on the physical and psychological 
symptoms of generalised anxiety, which we found were 
affected by sertraline.
Our results suggest that the main benefits in the first 
6 weeks of treatment with sertraline are on reduction of 
anxiety symptoms, such as worry and restlessness, rather 
than an improvement in depressive symptoms. Any 
effect on depressive symptoms takes longer to emerge 
and is more modest. However, an improvement in 
anxiety symptoms in someone presenting with 
depression could lead to a clinical benefit. In cases where 
there is uncertainty about prescribing an antidepressant, 
the presence of anxiety symptoms, such as worry and 
restlessness, could indicate an increased likelihood of 
benefit. Clinicians and patients should be aware of the 
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symptoms that are likely to improve so that they can 
consider alternative management of depressive symp-
toms that might not respond.
Our findings support the prescription of SSRI 
antidepressants in a wider group of participants than 
previously thought, including those with mild to 
moderate symptoms who do not meet diagnostic criteria 
for depression or generalised anxiety disorder.
We did not find evidence that treatment response for 
either anxiety or depressive symptoms varied according 
to the severity of depressive or anxiety symptoms, even 
within this heterogenous group of participants. There 
could be subgroups within this population that did not 
benefit from the anxiety reducing effect; however, in the 
absence of any evidence for such subgroups we conclude 
that our results should be generalisable to the broad 
group of people included in our study.
In conclusion, our finding that sertraline affects anxiety 
more quickly than depressive symptoms has potential 
implications for understanding the mechanisms of 
antidepressant treatment. Depressive symptoms could 
take longer to reduce than anxiety symptoms and some of 
the reduction might be explained by the earlier effects on 
anxiety. Our results also challenge our reliance on 
placebo-controlled studies that have been done primarily 
for regulatory purposes. Investigation of pharmacological 
treatments after regulatory approval is needed. SSRIs are 
among the most commonly prescribed medications in 
the world and yet we still have an imperfect knowledge of 
their clinical effectiveness and indications for their use.
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